227 Westminster N
About Corbin Therapeutics
Corbin Therapeutics is a Montreal-based biotech company, using a unique drug discovery platform to identify and develop novel USP15 inhibitors for treatment of various inflammation diseases, such as multiple sclerosis. This platform includes several in-vitro and in-vivo models for efficient drug screening and confirmation of potential lead candidates.
CEO: Véronique Bougie
CSO: Philippe Gros
5 articles with Corbin Therapeutics
Corbin Therapeutics, headquartered in Montreal, Quebec, was spun out of venture capital company AmorChem.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Corbin Therapeutics And Proteorex Therapeutics Announce A Research And Development Collaboration To Discover Novel Ubiquitin-Specific Protease Inhibitors
AmorChem l.p. Spins Out Its Usp15-Deubiquitinylation (Dub) Drug Discovery Platform Into Corbin Therapeutics, With A First 1M$ Seed Investment